Results 221 to 230 of about 111,907 (307)

Potential circadian rhythm-related pathogenic genes in diabetic nephropathy: a multi-omics Mendelian randomization study. [PDF]

Ren Fail
Mao Y, Zhang M, Li X, Zhang Z, Rong W, Zhang X, Feng L, Xu J.   +7 more
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Diagnostic Roles of circXPNPEP3 as Biomarker for Diabetic Nephropathy. [PDF]

Diabetes Metab Syndr Obes
Liu M, Zhan Q, Zhu J, Zhao J, Min D.
europepmc   +1 more source

Sudomotor dysfunction in people with type 1 diabetes with and without clinical peripheral neuropathy: A study from Pune, India

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Background and Aims It is appreciated that current screening tools for diabetic peripheral neuropathy (DPN) often fail to detect early disease. Sudomotor (sweat gland) dysfunction, among the earliest manifestations of DPN, can be measured objectively by the SUDOSCAN® device. We compared SUDOSCAN® with conventional validated screening (Michigan
Rohan Shah, Rishikesh Behere, Aboli Bhalerao, Sanat Phatak, Alma Baptist, Chinmay S. Marathe, Chittaranjan S. Yajnik   +6 more
wiley   +1 more source

Mechanisms of the Effects of Polyphenols on Diabetic Nephropathy. [PDF]

Curr Issues Mol Biol
Kamiyama M, Iijima K, Okuzawa R, Kawata R, Kimura A, Shinohara Y, Shimada A, Yamanaka M, Youda A, Iwamoto T.   +9 more
europepmc   +1 more source

Non-diabetic nephropathy in diabetics

Kidney Research and Clinical Practice, 2014
openaire   +3 more sources

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, EarlyView.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

Correction: Erythropoietin mitigates diabetic nephropathy by restoring PINK1/Parkin-mediated mitophagy. [PDF]

Front Pharmacol
Yi X, Yan W, Guo T, Liu N, Wang Z, Shang J, Wei X, Cui X, Sun Y, Ren S, Chen L.   +10 more
europepmc   +1 more source

Outcomes for Frail Dialysis Patients Not Referred for Transplantation: A Cohort Study

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Frailty is highly prevalent in kidney failure, but it is unclear whether frailty impacts health outcomes for those initiating dialysis who are not referred for transplantation. Our objective was to determine if frailty is associated with death or development of a permanent contraindication to transplantation among eligible non ...
Joshua Goodwin, Jordan Thorne, Amanda Vinson, David Clark, Bryce Kiberd, Micheal Sun, Karthik Tennankore   +6 more
wiley   +1 more source

Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects. [PDF]

Front Pharmacol
Yu Y, Tang H, Li N, Ge H, Wu J, Gu HF.
europepmc   +1 more source